G
Greenbrook
Provides innovative, non-invasive treatments like Transcranial Magnetic Stimulation (TMS) and Spravato® for depression and OCD
About Greenbrook
Greenbrook TMS NeuroHealth is the nation’s leading provider of Transcranial Magnetic Stimulation (TMS) therapy, an FDA-cleared, non-invasive therapy for the treatment of Major Depressive Disorder and Obsessive Compulsive Disorder. Since 2011, we’ve provided more than 320,000 life-changing TMS treatments to over 9,000 patients. Learn more at greenbrooktms.com
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2011
- Headquarters
- Tysons, United States
- Listing
- IPO 2018
- Sector
- Health
- Power Law
- Colt$25–100M revenue
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later1 investor entered at this stage
Madryn Asset Management
Source: Dealroom Talent Intelligence.
Global footprint
across markets
Market sentiment
An AI-synthesised read of the highest-engagement posts about Greenbrook on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Greenbrook on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.